Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Lenmeldy Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Lenmeldy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Lenmeldy (atidarsagene autotemcel), an autologous hematopoietic stem cell-based gene therapy, for eligible Medicare Advantage members with specified forms of metachromatic leukodystrophy. It applies to providers requesting administration through the medical benefit.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lenmeldy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request before Lenmeldy is administered under the Medicare Part B medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J3391Prior authorization code
    1 doseMaximum treatment course
    6 monthsApproval window
    2.0 × 10^6/kgBackup cell collection

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Covered disease stages
    0Replacement doses

    Lenmeldy Coverage Criteria

    Initial Lenmeldy Coverage

    Lenmeldy may be considered for coverage when ALL of the following are met:

    ALL of the following

    • Eligible MLD diagnosis

      • Member has a confirmed diagnosis of pre-symptomatic late infantile (PSLI) metachromatic leukodystrophy (MLD).
      • Member has a confirmed diagnosis of pre-symptomatic early juvenile (PSEJ) MLD.
      • Member has a confirmed diagnosis of early symptomatic early juvenile (ESEJ) MLD.
    • Diagnostic confirmation

      • Genetic confirmation of a mutation in the ARSA gene.
      • Biochemical testing

        • Sulfatase enzyme activity testing.
        • Urinary sulfatide excretion testing.
      • Brain MRI. An MRI can show the presence and absence of myelin; brain injury accumulates as the disease progresses. An initial MRI in pediatric members can appear normal.
    • Pediatric cases with an initially normal brain MRI are reviewed on a case-by-case basis.
    • Lenmeldy is prescribed by or in consultation with a neurologist or geneticist.
    • Chart notes document that the member does not have liver or renal impairment, supported by current renal and liver function tests.
    • Documentation confirms that the member will not receive live vaccines for 6 weeks prior to myeloablative conditioning for Lenmeldy and until hematological recovery following treatment with Lenmeldy.
    • For female members, a negative serum pregnancy test is confirmed.
    • The provider confirms that the member will not use prophylactic HIV antiretroviral medications for at least 1 month prior to mobilization or for the expected duration needed for elimination of the medications. Antiretroviral medications may interfere with Lenmeldy manufacturing. If a child requires antiretrovirals for HIV prophylaxis, Lenmeldy treatment should be delayed until a negative HIV test is confirmed.
    • Lenmeldy is administered at a treatment center appropriately certified to administer the product.
    • The manufacturer requirement for collection of unmanipulated back-up CD34+ cells of at least 2.0 × 10^6 CD34+ cells/kg is met, as confirmed by the provider.
    • Full myeloablative conditioning will occur prior to Lenmeldy administration, as confirmed by the provider.
    • Chart notes document current negative screening for HIV-1, HIV-2, HBV, HCV, HTLV-1, HTLV-2, CMV, and mycoplasma, and indicate that the member does not have active infection with any of these pathogens.
    • Current documentation confirms that the member does not have an active bacterial, viral, fungal, or parasitic infection.
    • Lenmeldy is approved as a one-time dose within 6 months.
    • The member remains eligible at the time of infusion.

    Lenmeldy is not covered when used outside FDA-approved package-labeling limits for age, dose, dosing frequency, or duration of therapy.

    Lenmeldy is not covered for a diagnosis of late juvenile metachromatic leukodystrophy (MLD).

    Lenmeldy is not covered for members with renal impairment or hepatic impairment.

    Lenmeldy is not covered when the member has been previously treated with Lenmeldy.

    Lenmeldy is not covered when the member is pregnant or planning to become pregnant.

    Lenmeldy is not covered when the member has tested positive for or has active HIV-1, HIV-2, HBV, HCV, HTLV-1, HTLV-2, CMV, or mycoplasma infection.

    Lenmeldy is not covered for members with an active bacterial, viral, fungal, or parasitic infection.

    Lenmeldy is not covered for use in combination with another autologous genome-edited hematopoietic stem cell-based gene therapy.

    Requests for replacement of lost or damaged Lenmeldy product will not be covered.

    Coding and Treatment Parameters

    Drugs Requiring Prior Authorization under the medical benefitHCPCSCovered
    J3391Lenmeldy (Atidarsagene Autotemcel)
    Backup CD34+ Cell Collection
    Collection typeUnmanipulated backup CD34+ cells
    Minimum collectionAt least 2.0 × 10^6 CD34+ cells/kg
    DocumentationProvider confirmation that the manufacturer requirement has been met
    Live-Vaccine Avoidance
    Vaccine restrictionNo live vaccines
    Start of avoidance period6 weeks prior to myeloablative conditioning for Lenmeldy
    End of avoidance period

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Lenmeldy (atidarsagene autotemcel) under the Medicare Part B medical benefit. The drug is administered through the pharmacy department; submit requests under HCPCS J3391 and refer to current CMS LCDs, NCDs, and Policy Articles when applicable.

    • Refer to the MVP Medicare website for Medicare Part D formulary and Part D policies; this requirement applies to the medical benefit.
    Billing Rule

    One-Time Approval Window

    Coverage is authorized for one Lenmeldy dose within a six-month approval window, subject to member eligibility at the time of infusion.

    • Replacement requests for lost or damaged product are not covered.

    Disease Background

    Metachromatic leukodystrophy is a rare, autosomal recessive, life-limiting lysosomal storage disease caused by mutations in the ARSA or SAPB gene. These mutations impair lysosomal degradation and lead to sulfatide accumulation throughout the body, causing progressive injury to the nervous system. The disease course may include gait abnormalities, speech regression, functional and cognitive loss, and seizures. Lenmeldy is an autologous hematopoietic stem cell-based gene therapy intended to add functional ARSA gene copies to the member’s own hematopoietic stem cells and is administered as a one-time treatment.

    Metachromatic Leukodystrophy Definitions

    PSLI MLD
    AbbreviationPSLI MLD
    Full termPresymptomatic late infantile metachromatic leukodystrophy
    Coverage statusAn eligible metachromatic leukodystrophy diagnosis for Lenmeldy coverage consideration
    PSEJ MLD
    AbbreviationPSEJ MLD
    Full termPresymptomatic early juvenile metachromatic leukodystrophy
    Coverage statusAn eligible metachromatic leukodystrophy diagnosis for Lenmeldy coverage consideration

    Initial Lenmeldy Therapy

    Initial Lenmeldy Therapy

    Initial treatment may be covered when all specified diagnostic, clinical, laboratory, preparation, and administration requirements are met.

    Initial therapy requirements

    • Diagnosis and confirmation: Member has pre-symptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy confirmed by ARSA mutation testing, biochemical testing including sulfatase enzyme activity and urinary sulfatide excretion, and brain MRI.

      An initially normal MRI in a pediatric member is reviewed case by case.

    • Clinical and specialist requirements: Lenmeldy is prescribed by or provided in consultation with a neurologist or geneticist, and the member does not have renal or hepatic impairment as documented by current renal and liver function tests.
    • Preparation requirements

    Lenmeldy Quantity and Duration

    Lenmeldy Quantity Limit
    DrugLenmeldy (atidarsagene autotemcel)
    Administration limitOne-time administration
    Approval windowApproved within a 6-month window

    Administration Site

    Billing Rule

    Administer at a certified infusion center

    Lenmeldy must be administered by an appropriately certified treatment center. Document the certified treatment center in the authorization request.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lenmeldy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request before Lenmeldy is administered under the Medicare Part B medical benefit.
    SourceLink
    On This Page
    Lenmeldy Coverage CriteriaCoding and Treatment ParametersAuthorization and Documentation RequirementsDisease BackgroundMetachromatic Leukodystrophy DefinitionsInitial Lenmeldy TherapyLenmeldy Quantity and DurationAdministration Site
    Until hematological recovery following treatment with Lenmeldy
    Antiretroviral Medication Management
    Medication restrictionProphylactic HIV antiretroviral medications
    Required avoidance periodAt least 1 month prior to mobilization or for the expected time needed for medication elimination
    If prophylaxis is requiredDelay Lenmeldy treatment until a negative HIV test is confirmed
    Approval Duration
    Administration frequencyOne-time dose
    Approval windowWithin 6 months
    Coverage conditionMember eligibility must be maintained at the time of infusion
  1. Confirm eligibility remains active before infusion.
  2. Unsupported block type: documentation

    Documentation Required

    Specialist Involvement

    Lenmeldy must be prescribed by, or administered in consultation with, a neurologist or geneticist. Submit the prescribing documentation or consultation notes.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Clinical Exclusions

    Lenmeldy is not covered when use falls outside FDA-approved package labeling for age, dose, dosing frequency, or duration, or when any listed clinical exclusion applies.

    • Late juvenile MLD.
    • Renal or hepatic impairment.
    • Previous treatment with Lenmeldy.
    • Pregnancy or plans to become pregnant.
    • Positive testing for or active infection with HIV-1, HIV-2, HBV, HCV, HTLV-1, HTLV-2, CMV, or mycoplasma.
    • Active bacterial, viral, fungal, or parasitic infection.
    • Use in combination with another autologous genome-edited hematopoietic stem cell-based gene therapy.
    ESEJ MLD
    AbbreviationESEJ MLD
    Full termEarly symptomatic early juvenile metachromatic leukodystrophy
    Coverage statusAn eligible metachromatic leukodystrophy diagnosis for Lenmeldy coverage consideration
    Metachromatic Leukodystrophy
    Disease typeRare, autosomal recessive, life-limiting lysosomal storage disease
    Associated genesMutations in the arylsulfatase A (ARSA) gene or sphingolipid activator protein B (SAPB) gene
    Biochemical featureAccumulation of sulfatides throughout the body
    Vaccination restriction: The member will not receive live vaccines for 6 weeks before myeloablative conditioning and until hematological recovery following treatment with Lenmeldy.6 weeks before conditioning through hematological recovery
  3. Pregnancy testing: For female members, a negative serum pregnancy test is confirmed.negative serum pregnancy test
  4. Antiretroviral restriction: The member will not use prophylactic HIV antiretroviral medications for at least 1 month before mobilization or for the expected time needed for elimination of the medications.at least 1 month before mobilization

    If HIV prophylaxis is required, treatment should be delayed until a negative HIV test is confirmed.

  5. Backup cell collection: The manufacturer requirement for collection of unmanipulated backup CD34+ cells is met.at least 2.0 × 10^6 CD34+ cells/kg
  6. Infection screening: Current screening is negative for HIV-1, HIV-2, HBV, HCV, HTLV-1, HTLV-2, CMV, and mycoplasma infection, with no active bacterial, viral, fungal, or parasitic infection.negative current screening; no active infection
  7. Administration requirements

    • Myeloablative conditioning: Full myeloablative conditioning will occur before Lenmeldy administration.full myeloablative conditioning before administration
    • Certified treatment center: Lenmeldy will be administered at an appropriately certified treatment center.
  8. Approval timing: Coverage is authorized for a one-time dose within 6 months and remains contingent on member eligibility at the time of infusion.one-time dose within 6 months